Trastuzumab Deruxtecan May Represent Potential Option for HE

Funda Meric-Bernstam, MD, discusses the design of the DESTINY-PanTumor02 trial, details the antitumor activity and safety of T-DXd in HER2-expressing solid tumors, and shares additional analyses that will be coming down the pike.

Related Keywords

Houston , Texas , United States , Corrs , Nellieb Connally , , Institute For Personalized Cancer Therapy , Phasei Program , Department Of Investigational Cancer Therapeutics , University Of Texas Md Anderson Cancer Center , Funda Meric Bernstam , Investigational Cancer Therapeutics , Personalized Cancer Therapy , Breast Cancer , Cancer Center , News , Neoadjuvant Her2 , Fam Trastuzumab Deruxtecan Nxki , Enhertu , T Dxd , Nct04482309 , Destiny Pantumor02 Trial ,